We observed that additional supplementation of the cocktail after adherence enables maintenance of the AML phenotype with higher expression of PPAR-γ, MRC1, and MARCO compared to cells that are not treated after adherence (Fig. S2A through C). The gene discussed is MARCO; the disease is acute myeloid leukemia.